Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 17/20 | 0.66 |
| ▸ | PTGER2 | P43116 | 14/20 | 0.66 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | GRK5 | P34947 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4077758 | 0.95 | PTGER4 (0.64) | PTGER4PTGER2PTGER3MEN1KMT2A | |
| SCHEMBL4087462 | 0.91 | PTGER4 (0.69) | PTGER4PTGER2PTGER3S1PR1GRK5 | |
| SCHEMBL4080468 | 0.90 | PTGER4 (0.60) | PTGER4PTGER2PTGER3MEN1KMT2A | |
| SCHEMBL4082505 | 0.88 | PTGER4 (0.64) | PTGER4PTGER2PTGER3 | |
| SCHEMBL4081966 | 0.88 | PTGER4 (0.62) | PTGER4PTGER2PTGER3MEN1KMT2A | |
| SCHEMBL4081035 | 0.86 | PTGER4 (0.62) | PTGER4PTGER2PTGER3MEN1KMT2A | |
| SCHEMBL4087547 | 0.85 | PTGER4 (0.58) | PTGER4PTGER2PTGER3MEN1KMT2A | |
| SCHEMBL4087561 | 0.85 | PTGER4 (0.60) | PTGER4PTGER2PTGER3MEN1KMT2A | |
| SCHEMBL27697646 | 0.84 | PTGER4 (0.66) | PTGER4PTGER2PTGER3MEN1KMT2A | |
| SCHEMBL4085414 | 0.84 | PTGER4 (0.92) | PTGER4PTGER2PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1847533-B1 | SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-7531533-B2 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-05-12 | — | — | US | disclosed |
| EP-1847533-A1 | SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | WNT1, CYP11B2, CYP11B1 | PTGER4 33/4885PTGER2 39/4885PTGER3 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.